PinCell
4.5.2023 10:01:39 CEST | ACCESS Newswire | Press release
Proprietary transgenic mouse produces human form of FasL protein
MILAN, ITALY / ACCESSWIRE / May 4, 2023 / PinCell, a biotechnology company developing a first-in-class therapy for rare and debilitating autoimmune skin diseases, announced the successful completion of two independent in-vivo studies of its lead candidate (PC111) using a proprietary transgenic mouse model expressing the human form of the target protein (FasL). PinCell is a spin-off of the University of Modena and Reggio Emilia and was seed financed by Sofinnova Partners, a leading European venture capital firm based in Paris, London and Milan.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.PinCell's monoclonal antibody, PC111, proved effective in the neonatal passive pemphigus mouse model, considered the gold standard for testing treatments of pemphigus, a rare and debilitating skin disease marked by extreme blistering of skin and mucosae. Using the proprietary transgenic mouse, PC111 inhibited the production of blisters by at least 80%, confirming previous studies in in-vitro and ex-vivo human models of pemphigus. PC111 was also shown to dose-dependently neutralize human FasL in another in-vivo setting involving the Concanavalin-A liver model, which induces an acute release of FasL into the blood.
"This is a great achievement for the company," said Dr. Antonino (Tony) Amato, Chief Executive Officer of PinCell. "It provides for the first time in-vivo proof of concept evidence of PC111 effect in a humanized disease setting."
"We feel a real sense of accomplishment," said Prof. Carlo Pincelli, founder and Chief Medical Officer at PinCell. "By developing a proprietary model, we have now shown that our antibody does indeed inhibit blister formation by binding specifically to the human target."
"What is more, the humanized FasL mouse model could prove to be a valuable tool to study the involvement of the Fas/FasL pathway in other diseases in which this pathway may play a key role in disease development and progression," Prof. Pincelli added.
About pemphigus
Pemphigus is a rare condition that affects about 300,000 patients worldwide. Conservatively, a treatment based on PC111 would be beneficial for over 30 percent of this population who are relapsing or refractory to first line treatments.
PinCell's therapy will be an alternative to steroids or immunosuppressants currently prescribed or under development. By acting downstream from the immune system, at the level of skin cells, PC111's innovative mode of action will contribute to the reduction or the avoidance of steroids/immunosuppressants, while showing a rapid onset of action.
About PinCell
PinCell is a biotechnology company targeting a novel pathological pathway to develop first-in-class anti-inflammatory therapies for the treatment of rare, severe and highly undertreated skin diseases. Based in Milan, Italy, PinCell was founded in October 2008 as an academic spin-off of the University of Modena and Reggio Emilia by the world-class dermatology experts Prof. Carlo Pincelli and Prof. Alessandra Marconi. PinCell received seed funding from Sofinnova Partners.
For more information, please visit: www.pincell.it
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management. For more information, please visit: sofinnovapartners.com
CONTACT: Tony Amato, MD - CEO, PinCell - a.amato@pincell.com - +39-334-6263471
SOURCE: PinCell
View source version on accesswire.com:
https://www.accesswire.com/752528/PinCell-Announces-2-Successful-In-Vivo-Studies-for-Breakthrough-Skin-Disease-Therapy
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Lithium Measurement MR-Technology Provider NanoNord Expands Business with DLE Leader ElectraLith, Following Danish State Visit to Australia25.3.2026 13:30:00 CET | Press release
Danish company expands collaboration with Australian deeptech rising star during the Royal State Visit to Melbourne AALBORG, DENMARK AND MELBOURNE, AU / ACCESS Newswire / March 25, 2026 / The North Jutland technology company NanoNord has, in connection with the Royal Couple's state visit to Australia, secured an order for additional measurement equipment valued at between 160k - 240k AUD from the Australian deeptech pioneer ElectraLith. The order underscores the growing international potential for Danish measurement technology in the green transition. NanoNord was part of the business delegation during the state visit and seized the opportunity to strengthen its business with both existing and new customers in Australia. It is not the first time the Danish Royal Family has been close to NanoNord - the company was originally officially inaugurated by a then-young Crown Prince Frederik. Danish Technology Measures Lithium in Real Time NanoNord's flagship technology, Tveskaeg, is an MR-bas
Rancho BioSciences Appoints Chris O'Brien as CEO to Deliver AI-Ready Data Solutions for Faster, More Reliable R&D25.3.2026 13:00:00 CET | Press release
Veteran life sciences leader to drive enterprise growth and expand adoption of AI-ready data solutions across pharma and biotech SAN DIEGO, CA / ACCESS Newswire / March 25, 2026 / Rancho BioSciences today announced the appointment of Chris O'Brien as Chief Executive Officer. O'Brien will lead the company's next phase of growth as Rancho expands adoption of its AI-ready data solutions across pharmaceutical, biotechnology, and research organizations. Rancho BioSciences delivers AI-ready data solutions that transform fragmented biomedical data into standardized, reusable assets for AI, analytics, and machine learning. As life sciences organizations continue investing in AI and advanced analytics, preparing inconsistent and siloed data remains a major bottleneck-often slowing analysis and limiting reuse across programs. Rancho addresses this by standardizing and harmonizing complex data so it can be used immediately and consistently across the R&D lifecycle. O'Brien brings more than 20 yea
Datavault AI Partners with Rising British Heavyweight Moses Itauma25.3.2026 13:00:00 CET | Press release
21-Year-Old Boxing Phenom to Showcase Datavault AI Brand in Manchester Showdown Against Jermaine Franklin PHILADELPHIA, PA / ACCESS Newswire / March 25, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced that it has entered into a partnership agreement with undefeated British heavyweight boxing sensation Moses Itauma. The 21-year-old Commonwealth champion's highly anticipated bout against Jermaine Franklin will be on March 28, 2026, at the Co-op Live Arena in Manchester, England, and will be broadcast globally on DAZN. The partnership reflects Datavault AI's strategic focus on elite combat sports talent as the Company builds out its athlete name, image, and likeness ("NIL") digital asset exchange platform, being developed in exploratory collaboration with Sports Illustrated. Itauma (13-0, 11 KOs) is widely regarded as one of
GA-ASI's UK and Japan MQ-9B Programs Are Honored With Excellence Awards from Aviation Week24.3.2026 20:00:00 CET | Press release
GA-ASI Wins 2 of the 9 Awards Presented SAN DIEGO, CA / ACCESS Newswire / March 24, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) was named the winner of two awards during Aviation Week's 21st annual Program Excellence Awards last week. GA-ASI's United Kingdom (UK) Protector Program was given the Special Projects Award, while its Japan COCO (Company-Owned, Company-Operated) Program won in the category of OEM System Sustainment. "We're excited that these two important MQ-9B international programs have been recognized by Aviation Week," said GA-ASI CEO Linden Blue. "We're fortunate to have an incredible team of employees whose dedication and commitment to our customers is truly remarkable." MQ-9B is GA-ASI's most advanced Remotely Piloted Aircraft (RPA) system and includes the SkyGuardian® and SeaGuardian® models, as well as the UK's Protector RG Mk1. In 2025, GA-ASI achieved the first-ever Military Type Certificate (MTC) for the Royal Air Force's (RAF) Protector RG Mk1, pas
Professional Services Firms Bet Big on AI but Skills Gaps Are Holding Them Back, General Assembly Survey Finds24.3.2026 14:00:00 CET | Press release
Most firms have had to abandon at least one AI initiative due to a lack of skills in the past year NEW YORK, NY / ACCESS Newswire / March 24, 2026 / Most professional services firms (61%) have had to abandon at least one AI initiative in the past year due to a lack of internal skills, with more than a third (35%) abandoning multiple initiatives, according to new research from General Assembly, the global leader in practical AI skills training and an LHH company. "Professional services firms face a capability paradox," said Ash Khanna, Head of Professional Services at General Assembly. "AI can accelerate output, but it can't replace the judgment that comes from doing the hard work. We're seeing junior talent generate recommendations faster than ever, but struggle to defend the reasoning behind them. Firms must invest in the durable human skills that make AI output credible and defensible. Upskilling can't be an afterthought; it has to be as central to a firm's AI strategy as the technol
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom